Information about the 2019 Novel Coronavirus
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Trial ID or NCT#
The purpose of this study is to evaluate the safety and efficacy of Revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.
Contact us to find out if this trial is right for you.